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OBJECTIVES We sought to determine whether the observed benefits of enoxaparin were maintained
beyond the early phase; a one-year follow-up survey was undertaken for patients enrolled in
the Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q wave Coronary Events
(ESSENCE) study.
BACKGROUND We have previously reported a significant benefit of low molecular weight as compared with
unfractionated heparin (UFH) in the 14- and 30-day incidence of a composite end point of
death, myocardial infarction (MI) or recurrent angina in patients with unstable angina or
non–Q wave MI.
METHODS The study recruited 3,171 patients with recent-onset rest angina and underlying ischemic
heart disease. All patients received oral aspirin daily and were randomized to receive
enoxaparin subcutaneously every 12 h or UFH (intravenous bolus followed by continuous
infusion) in a double-blind, double-dummy fashion for a median of 2.6 days.
RESULTS The incidence of the composite triple end point at one year was lower among patients
receiving enoxaparin as compared with those receiving UFH (32.0% vs. 35.7%, p 5 0.022),
with a trend toward a lower incidence of the secondary composite end point of death or MI
(11.5% vs. 13.5%, p 5 0.082). At one year, the need for diagnostic catheterization and
coronary revascularization was lower in the enoxaparin group (55.8% vs. 59.4%, p 5 0.036
and 35.9% vs. 41.2%, p 5 0.002, respectively).
CONCLUSIONS In patients with unstable angina or non–Q wave MI, enoxaparin therapy significantly reduced
the rates of recurrent ischemic events and invasive diagnostic and therapeutic procedures in
the short term with sustained benefit at one year. (J Am Coll Cardiol 2000;36:693–8) ©
2000 by the American College of Cardiology
Coronary artery atherosclerotic plaque disruption with ac-
companying platelet adhesion and aggregation, as well as
thrombosis, plays a fundamental role in the pathogenesis of
unstable angina, acute myocardial infarction (MI) and
sudden death (1). A meta-analysis (2) of several randomized
clinical trials described a 44% relative risk reduction of MI
or death with combined aspirin and unfractionated or low
molecular weight heparin (LMWH) therapy in patients
with unstable angina or non–Q wave MI. However, despite
the dramatic short-term effect, most studies have been
limited to short-term outcomes (2) or have failed to dem-
onstrate sustained benefit of this antithrombotic regimen
(3,4).
We have previously reported a significant benefit of
LMWH as compared with unfractionated heparin (UFH),
along with aspirin therapy, in the 14-day incidence of death,
MI or recurrent angina in patients with unstable angina or
non–Q wave MI (5). The Efficacy and Safety of Subcuta-
neous Enoxaparin in Non–Q wave Coronary Events
(ESSENCE) trial demonstrated continued benefit of
LMWH therapy administered for a median duration of 2.6
days in the primary composite end point at 30 days, with a
trend toward lower death or MI rates and a significant
reduction in the need for coronary revascularization.
To determine whether the observed benefits of enoxapa-
rin plus aspirin, as compared with UFH plus aspirin, in
patients with unstable angina or non–Q wave MI were
maintained beyond the early (14 to 30 days) phase, a
one-year follow-up survey was undertaken for all patients
enrolled in the ESSENCE study.
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METHODS
Patient group. The entry criteria for enrollment, study
design and treatment protocol, as well as end point defini-
tions, of the ESSENCE study have been described in detail
(5). Briefly, 3,171 patients were enrolled at 176 centers in
Canada, the United States, Europe and South America.
Patients had recent-onset rest angina occurring within 24 h
before randomization and were required to have evidence of
underlying ischemic heart disease, as manifested by one of
three criteria: 1) new ST segment depression of at least
0.1 mV, transient ST segment elevation or T wave changes
in at least two contiguous leads; 2) documented previous MI
or coronary revascularization procedure; or 3) results of
noninvasive or invasive testing demonstrating ischemic
heart disease. Written, informed consent was obtained from
all patients, and the study was approved by the Institutional
Review Board of each participating hospital.
Study design and treatment protocol: primary analysis.
Patients were randomized to receive (double-blind, double-
dummy) either 1 mg/kg body weight of enoxaparin (Rhone-
Poulenc Rorer Corp., Collegeville, Pennsylvania; 100 anti-
factor Xa U/kg) subcutaneously every 12 h and an
intravenous placebo bolus and infusion, or subcutaneous
placebo injections and an intravenous bolus of UFH (usually
5,000 U), followed by a continuous infusion at a dose
adjusted according to the activated partial thromboplastin
time. Trial therapy was administered for a minimum of 48 h
and up to a maximum of eight days. All patients received
100 to 325 mg/day of oral aspirin. All other medications,
the decision to proceed with cardiac catheterization and the
use of coronary revascularization were left to the discretion
of the investigator.
The primary outcome of the trial was the composite triple
end point of death, nonfatal MI (or reinfarction) or recur-
rent angina at 14 days.
Study methods and end point definitions: one-year
follow-up. One-year follow-up was obtained in a retro-
spective manner, with each site responsible for telephone
contact of all randomized patients (or their physicians), case
report form completion and appropriate supporting docu-
mentation concerning end points and procedures per-
formed. In the United States, a death registry was also
employed in cases where patients were lost to follow-up. All
information was verified independently by an end points
committee whose members had reviewed all end points
during the initial 30-day study period and who were
unaware of treatment assignments.
For the one-year follow-up, the same composite triple
end point of death, MI or recurrent angina was used, and
the time to first composite triple end point was the primary
outcome. Secondary aims were to assess the time to the first
composite double end point of death or MI, cardiac cath-
eterization or coronary revascularization and to assess the
incidence of rehospitalization.
The confirmation of end points during the one-year
follow-up was based on the following definitions. Death was
defined as any death, regardless of cause. Cardiac arrest
from which the patient was resuscitated was also classified as
death. De novo MI was defined as 1) a total creatine kinase
(CK) concentration of more than twice the upper limit of
normal and an above-normal concentration of CK, MB
fraction (CK-MB) (at least 3% of total CK); or 2) in the
absence of CK or CK-MB measurements, new Q waves
.0.04 s in at least two leads. Perioperative MI was defined
as an elevation of total CK to five times the upper limit of
normal or new Q waves .0.04 s in at least two leads. A
diagnosis of MI after a percutaneous coronary intervention
(PCI) was made if the total CK concentration increased to
three times the upper limit of normal and at least 50% above
the previous nadir value. Recurrent angina during the 30-day
to one-year follow-up was defined as recurrent chest pain
leading to revascularization or rehospitalization.
Statistical analysis. The analyses were done according to
the intention-to-treat principle. Statistical comparisons be-
tween treatment groups were made using the time to event
with the Kaplan-Meier survival technique (two-sided, log-
rank test, alpha 5 0.05). In measuring the time to an event
for cases in which a patient had multiple end points, the first
event was taken into account. All patients without events
and lost to follow-up were censored at the time of study
termination or last contact. In some cases where it was only
possible to establish whether a patient was alive or dead, the
confirmation date determined the length of follow-up for
mortality. However, if an earlier date was known at which
full information (and not simply mortality) was available,
that date determined the length of follow-up in the analysis
of all events. Subgroup analyses were performed using
univariate Cox regression models, and treatment effects
were estimated by a hazard ratio with the 95% confidence
interval (CI).
RESULTS
Short-term outcome. Figure 1 shows the flow of patients
through the trial. As reported previously (5), the incidence
of the composite triple end point (death, MI or recurrent
angina) at 14 days (primary end point) and 30 days was
significantly lower among the patients assigned to enoxapa-
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rin than among those assigned to UFH (16.6% vs. 19.8%,
p 5 0.019, odds ratio (OR) 0.80, 95% CI 0.67 to 0.96; and
19.8% vs. 23.3%, p 5 0.016, OR 0.81, 95% CI 0.68 to 0.96,
respectively). The secondary composite end point of death
or MI was reached at 30 days in 6.2% of the enoxaparin
group as compared with 7.7% of the UFH group (p 5
0.081, OR 0.79, 95% CI 0.59 to 1.03).
One-year outcome. Of the 3,171 patients enrolled, 87
(2.7%) died within the initial 30-day follow-up period. Only
16 patients (0.5%) had no follow-up information beyond 30
days. Complete one-year follow-up event information was
available in 2,915 patients (91.9%) (91.4% in the enoxaparin
group and 92.5% in the UFH group), and complete one-
year vital status was available in 2,992 patients (94.4%)
(94.4% in the enoxaparin group and 94.3% in the UFH
group); thus, some degree of follow-up data beyond 30 days
were available in 99.5% of patients.
Selected baseline characteristics and final diagnoses of the
overall patient cohort are shown in Table 1, according to
whether one-year follow-up information was available. As
compared with patients with one-year follow-up, those with
less than one-year follow-up had several lower risk charac-
teristics, including younger age and more frequent presen-
tation with no electrocardiographic (ECG) changes, and
were more likely to have a final diagnosis (as determined by
the local site investigator) of the qualifying chest pain of
noncardiac origin (14.5% vs. 5.5%, p , 0.0001). There was
no significant difference in any baseline variable between the
two treatment groups among patients with one-year follow-
up.
The incidence of the composite triple end point at one
year was significantly lower in the enoxaparin group as
compared with the UFH group (intention-to-treat analysis:
32.0% vs. 35.7%, p 5 0.022, hazard ratio 0.87, 95% CI 0.77
to 0.98). Figure 2 shows the Kaplan-Meier estimates of the
time to the first triple end point (death, MI or recurrent
angina) and double end point (death or MI) in the 12
months after randomization.
Among the patients who received at least one dose of
study medication, enoxaparin was also more effective than
UFH (efficacy analysis: 32.0% vs. 35.9%, p 5 0.018).
Consistent with the 30-day finding (5), enoxaparin was
significantly more effective than UFH in reducing the
primary composite triple end point among several high risk
subgroups, including those with previous aspirin use and
those with any ECG changes at baseline or ST segment
depression at baseline.
The trend toward a lower incidence of the secondary
Figure 1. Trial profile.
Table 1. Baseline Characteristics and Final Diagnosis According to Whether Complete One-
Year Follow-Up Information was Available
Characteristic
<1-Year
Follow-Up
1-Year
Follow-Up
p
Value
Patients randomized (n) 256 2,915
Patients treated (n) 240 (94%) 2,867 (98%)
Median age (years [range]) 58 (27–88) 65 (25–94) 0.0001
Median weight (kg [range]) 80 (41–152) 78 (33–182) 0.044
Female 28% 34% 0.045
Risk factors
Current smoker 36% 23% , 0.0001
Hypertension 59% 54% 0.12
Hypercholesterolemia 40% 45% 0.15
Diabetes mellitus 23% 22% 0.81
Previous cardiac history
Positive cardiac catheterization 45% 43% 0.001
MI 49% 46% 0.58
Coronary artery bypass graft surgery 22% 19% 0.52
Coronary angioplasty 25% 21% 0.013
Electrocardiographic changes 48% 57% 0.005
ST segment elevation 7% 7% 0.74
ST segment depression 15% 24% 0.001
T wave inversion 36% 39% 0.30
Final diagnosis
Unstable angina 68% 69% 0.58
Non–Q wave MI 15% 21% 0.013
Evolving Q wave MI 3% 4% 0.52
Noncardiac chest pain 14% 6% , 0.001
MI 5 myocardial infarction.
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composite end point of death or MI seen at 30 days in the
enoxaparin group as compared with the UFH group re-
mained at one year (11.5% vs. 13.5%, p 5 0.082, hazard
ratio 0.84, 95% CI 0.69 to 1.02).
Cardiac catheterization and revascularization. Thirty
days after randomization, the need for diagnostic cardiac
catheterization and coronary revascularization was signifi-
cantly less among the patients assigned to enoxaparin than
among those assigned to UFH (47.9% vs. 51.9%, p 5 0.024
and 27.0% vs. 32.2%, p 5 0.001, respectively).
At one-year follow-up, the requirement for diagnostic
catheterization and coronary revascularization remained sig-
nificantly less in the enoxaparin group as compared with the
UFH group (55.8% vs. 59.4%, p 5 0.036, hazard ratio 0.91,
95% CI 0.83 to 0.99 and 35.9% vs. 41.2%, p 5 0.002,
hazard ratio 0.84, 95% CI 0.75 to 0.94, respectively) (Fig.
3). In particular, patients assigned to enoxaparin as com-
pared with UFH required PCI less frequently (18.5% vs.
22.8%, p 5 0.004, hazard ratio 0.79, 95% CI 0.68 to 0.93).
Hospital admission. Among the 3,051 patients (96.2%)
with complete medical resource data during the first 30
days, initial intensive care unit and total length of stay were
similar among those patients assigned to enoxaparin and to
UFH (mean [6SD] duration 2.8 6 3.4 vs. 3.0 6 3.8 days,
p 5 0.26; and 8.2 6 6.4 vs. 8.5 6 6.7 days, p 5 0.28,
respectively). From 31 days to one year, rehospitalization for
any cause occurred in 27.9% of patients receiving enoxaparin
and 28.3% of patients receiving UFN (mean [6SD] dura-
tion of intensive care unit and total length of hospital stay:
1.0 6 4.8 vs. 1.3 6 5.4 days, p 5 0.24; and 4.7 6 13.9 vs.
4.8 6 12.8 days, p 5 0.49, respectively).
DISCUSSION
Advantages of LMWH therapy. Although oral aspirin
and intravenous UFH represent the current standard of care
for patients admitted to the hospital with unstable angina or
non–Q wave MI, this antithrombotic approach has a
substantial failure rate: recurrent ischemic chest pain, MI or
death occurs in 15% to 30%, and 15% to 25% of patients
undergo coronary revascularization within 12 weeks of
treatment initiation (2). This failure rate is likely due, in
part, to the marked variability in dose response and dose-
dependent clearance of UFH (6). In contrast, the reduced
binding of LMWH to plasma proteins, endothelial cells and
macrophages is associated with high bioavailability after
subcutaneous injection, a longer plasma half-life, dose-
independent clearance and a more predictable anticoagulant
response. Further advantages of LMWH include greater
resistance to inhibition by activated platelets, less platelet
activation, reduced release of von Willebrand factor, mini-
mal effect on microvascular permeability, a lower incidence
of heparin-induced thrombocytopenia and no need for
monitoring of activated partial thromboplastin time (6).
Low molecular weight heparins also have a higher anti-
factor Xa/IIa ratio and more tissue factor pathway inhibi-
tion, leading to greater inhibition of thrombin generation
and activity (6).
Previous trials with LMWH. A significant advantage of
combination LMWH and aspirin versus aspirin alone was
demonstrated during the first six days of treatment in 1,506
patients in the FRagmin during InStability in Coronary
artery disease (FRISC) study (3). This benefit was main-
tained during the following 35 to 40 days of ongoing once
daily subcutaneous dalteparin therapy; however, by four to
five months after the end of dalteparin treatment, the initial
reduction in death, MI and need for coronary revascular-
ization was no longer significant. Furthermore, on termina-
tion of treatment after six weeks, there was a trend toward
an increased frequency of ischemic events in the dalteparin
group in comparison with the placebo group, despite the
concurrent use of aspirin.
The superiority of LMWH as compared with UFH was
Figure 2. Kaplan-Meier plots of the time to a first event over a period of
one year for the composite triple end point of death, MI or recurrent angina
and for the composite double end point of death or MI.
Figure 3. Kaplan-Meier plots of the time to a first diagnostic cardiac
catheterization and the time to a first coronary revascularization over a
period of one year.
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first demonstrated by Gurfinkel et al. (7) in 219 patients
with unstable angina. In a randomized, open-label trial,
nadroparin plus aspirin was more effective than either UFH
plus aspirin or aspirin alone in the reduction of in-hospital
cardiac outcomes (7); no long-term data were collected in
this pilot study. However, the FRAXiparine in Ischaemic
Syndrome (FRAXIS) study of 3,468 patients with unstable
angina or non–Q wave MI failed to demonstrate an advan-
tage of subcutaneous nadroparin (administered for 6 6 2
days or 14 days, respectively) over intravenous UFH (6 6 2
days) during the short- (six or 14 days) or intermediate-term
(three months) follow-up period (8).
Another direct comparison of UFH and LWMH therapy
in 1,482 patients showed no difference in efficacy in the
hospital phase of the FRagmin In unstable Coronary artery
disease study (FRIC) (4). Furthermore, there was no benefit
of continued use of once daily dalteparin as compared with
aspirin alone up to 45 days after treatment initiation.
Results of ESSENCE. In contrast, the ESSENCE study
demonstrated both early (14 and 30 days) and sustained
benefit (one year) with a twice daily subcutaneous injection
of enoxaparin as compared with continuous UFH infusion.
ESSENCE is the first large-scale trial showing one-year
benefit of antithrombotic therapy administered for a rela-
tively brief duration of 2.6 days to patients with nonpersis-
tent ST segment elevation acute coronary syndromes. Al-
though the clinical benefit with enoxaparin was established
early (relative risk reduction of 16% at 48 h and maintained
at 14 and 30 days), the similar benefit of enoxaparin on the
rates of recurrent angina, MI, death, cardiac catheterization
and coronary revascularization, as well as rehospitalization
from 31 days to one year, indicates no clinical evidence of
greater late reactivation of disease after enoxaparin as
compared with standard heparin therapy.
There was a 1.5% absolute reduction in 30-day and 2%
absolute reduction in one-year death or MI rates with
enoxaparin as compared with UFH in the ESSENCE
study. This is similar to the absolute benefit seen over 30
days (1.6%) and six months (2%) in a meta-analysis of
patients with unstable angina or non–Q wave MI from all of
the randomized trials of intravenous platelet glycoprotein
IIb/IIIa receptor antagonists as compared with, or in addi-
tion to, UFH (9). However, additional information regard-
ing the magnitude of the benefit seen with enoxaparin is
required, because the number of patients in the ESSENCE
study is modest (n 5 3,171) in comparison to the four
IIb/IIIa receptor antagonist trials combined (n 5 18,031).
Results of ESSENCE and TIMI 11B. The Thrombolysis
In Myocardial Infarction (TIMI)-11B study (10) was a
randomized, double-blind, placebo-controlled trial compar-
ing the strategy of combined short-term ($72 h) and
intermediate-term (43 days) administration of enoxaparin
versus UFH for patients with unstable angina or non–Q
wave MI during the early phase. The results of this
3,910-patient trial confirm the benefit seen with enoxaparin
over heparin in the ESSENCE trial, at 14 and 43 days,
respectively. Furthermore, a meta-analysis of both trials
(n 5 7,081) demonstrates a significant reduction in the
triple end point of death, MI or recurrent ischemia requir-
ing urgent revascularization, as well as the double end point
of death or MI up to 43 days (11); longer term (one year)
follow-up in TIMI-11B is also consistent with the
ESSENCE results (12).
Comparisons with other LMWHs. A number of reasons
could account for the apparent inconsistency of efficacy
findings between the trials evaluating dalteparin (FRIC)
and nadroparin (FRAXIS) and the studies (ESSENCE and
TIMI-11B) that have demonstrated an advantage over
UFH. First, the LMWHs vary in their average molecular
weight, patterns of distribution of glycosaminoglycan
chains, anti-factor Xa/IIa ratio and release profile of tissue
factor pathway inhibitor. Second, the anti-thrombotic doses
of both the LMWHs and UFH were different in each of the
clinical trials. Third, there were differences in trial design,
including the time from the qualifying episode of chest
discomfort to study enrollment, patient risk profile (e.g.,
proportion of patients with ECG changes, non–Q wave
MI) and end point definitions (e.g., recurrent angina, MI).
Thus, in addition to the play of chance, a number of factors
could have played a role in demonstrating a significant and
sustained advantage of enoxaparin (ESSENCE and TIMI-
11B), whereas others failed to show a benefit of LMWH
over UFH (FRIC and FRAXIS).
Future treatment. Particularly in view of the cost-
effectiveness of enoxaparin (13,14), it is likely that optimal
short-term treatment of high risk patients with acute
ischemic coronary syndromes without persistent ST seg-
ment elevation in the near future will include a combination
of oral aspirin, subcutaneous LMWH and intravenous
glycoprotein IIb/IIIa receptor antagonists.
Despite the modest benefit of enoxaparin in the
ESSENCE study, it is sobering to note that the event rates
in patients who present without persistent ST segment
elevation acute coronary syndromes remain high at both 30
days (20%) and one year (32%). Indeed, death or (re)infarc-
tion occur in 6 of 100 patients by 30 days, despite aspirin,
short-term enoxaparin therapy and a coronary revascular-
ization rate of 27%. An additional six deaths or MIs (per
100 patients) occur despite on-going aspirin therapy, and
the revascularization rate is 9% from 31 days to one year.
The high risk of recurrent ischemic events likely relates to
the fact that the underlying lesion in the coronary artery
remains active, with accompanying thrombin generation for
many weeks after the initial plaque rupture, leading to the
initial episode (15,16). Despite its modest antiplatelet ac-
tivity, aspirin has only an indirect effect on thrombin
generation or activity, and further clinical event prevention
may require continued antithrombotic therapy after the
initial phase of treatment. In addition, there is evidence
from the FRISC II study to suggest that a more aggressive
approach (early cardiac catheterization plus revasculariza-
tion, when appropriate) to moderate to high risk patients
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with unstable angina or non–Q wave MI leads to a lower
incidence of six-month death and (re)infarction (17).
Role of enoxaparin in unstable angina or non–Q wave
MI. Treatment with enoxaparin in addition to aspirin
should be considered for at least 48 to 72 h in patients with
unstable angina or non–Q wave MI to reduce the short- and
long-term risk of recurrent angina, myocardial (re)infarction
or death. This antithrombotic strategy will also lead to a
lower requirement for diagnostic catheterization (approxi-
mately four less per 100 patients) and coronary revascular-
ization (approximately one less coronary artery bypass graft
surgeries and four less percutaneous procedures per 100
patients) by one year. The simple mode of administration
without the need for anticoagulation monitoring, lower
requirement for invasive diagnostic and therapeutic proce-
dures, cost savings and superior short-term and sustained
long-term efficacy make enoxaparin an attractive option in
the treatment of patients with acute ischemic coronary
syndromes presenting without persistent ST segment eleva-
tion.
Acknowledgments
The authors acknowledge the outstanding efforts of all study
coordinators and investigators in obtaining follow-up status
and information on the ESSENCE study participants and
the other End Point Adjudication Committee Members
(Leonard Dreifus, MD, and John Kostis, MD), Francoise
Gosset (CRA Coordinator) and Patrick Poinot (Data Man-
ager).
Reprint requests and correspondence: Dr. Shaun G. Goodman,
St. Michael’s Hospital, Division of Cardiology, 30 Bond Street,
Room 9-005 Queen, Toronto, Ontario, Canada M5B 1W8.
E-mail: goodmans@smh.toronto.on.ca.
REFERENCES
1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of
coronary artery disease and the acute coronary syndromes (2). N Engl
J Med 1992;326:310–8.
2. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin
reduces the incidence of myocardial infarction and death in patients
with unstable angina: a meta-analysis. JAMA 1996;276:811–5.
3. FRagmin during InStability in Coronary artery disease (FRISC) Study
Group. Low-molecular-weight heparin during instability in coronary
artery disease. Lancet 1996;347:561–8.
4. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-
weight heparin with unfractionated heparin acutely and with placebo
for six weeks in the management of unstable coronary artery disease:
FRagmin In unstable Coronary artery disease (FRIC) Study. Circu-
lation 1997;96:61–8.
5. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-
molecular-weight heparin with unfractionated heparin for unstable
coronary artery disease. N Engl J Med 1997;337:447–52.
6. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:
688–98.
7. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight
heparin versus regular heparin or aspirin in the treatment of unstable
angina and silent ischemia. J Am Coll Cardiol 1995;26:313–8.
8. The FRAXIS Study Group. Comparison of two treatment durations
(6 days and 14 days) of a low molecular weight heparin with a 6-day
treatment of unfractionated heparin in the initial management of
unstable angina or non–Q wave myocardial infarction: FRAXIS
(FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553–
62.
9. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of
therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin
in ischemic heart disease. Circulation 1998;98:2829–35.
10. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin for the
acute and chronic management of unstable angina/non–Q wave
myocardial infarction: results of TIMI 11B. Circulation 1999;100:
1593–601.
11. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment
effect of enoxaparin for unstable angina/non–Q-wave myocardial
infarction: TIMI 11B–ESSENCE meta-analysis. Circulation 1999;
100:1602–8.
12. Antman EM, McCabe CH, Gurfinkel EP, et al. Treatment benefit of
enoxaparin in unstable angina/non–Q wave myocardial infarction is
maintained at one year follow-up in TIMI 11B (abstr). Circulation
1999;100 Suppl I:I–497.
13. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of
low molecular weight heparin (enoxaparin) versus unfractionated
heparin in acute coronary syndrome patients: results from the
ESSENCE randomized trial. Circulation 1998;97:1702–7.
14. O’Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman
S. Is the use of low-molecular-weight heparin (enoxaparin) in acute
coronary syndrome patients cost saving in Canada? Am Heart J
2000;139:423–9.
15. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of
coagulation mechanism in unstable angina and myocardial infarction.
Circulation 1994;90:61–8.
16. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations
of coagulation and fibrinolytic and kallikrein-kinin systems in the acute
and postacute phases in patients with unstable angina. Circulation
1995;91:2520–7.
17. FRagmin and fast revascularisation during InStability in Coronary
artery disease (FRISC II) Investigators. Long-term low molecular
mass heparin in unstable coronary artery disease: FRISC II prospective
randomised multicentre study. Lancet 1999;354:701–7.
698 Goodman et al. JACC Vol. 36, No. 3, 2000
One-Year Results of the ESSENCE Study September 2000:693–8
